Institutional members access full text with Ovid®

Share this article on:

RETINAL SENSITIVITY AFTER PHOTODYNAMIC THERAPY WITH HALF-DOSE VERTEPORFIN FOR CHRONIC CENTRAL SEROUS CHORIORETINOPATHY: Short-Term Results

Fujita, Kyoko MD; Yuzawa, Mitsuko MD; Mori, Ryusaburou MD

doi: 10.1097/IAE.0b013e3181f049d3
Original Study

Background: To assess retinal sensitivity after photodynamic therapy (PDT) with half-dose verteporfin in patients with chronic central serous chorioretinopathy.

Methods: Sixteen eyes with chronic chorioretinopathy treated using PDT with half-dose verteporfin were enrolled. Microperimetry covering the central area 12 degrees in diameter was performed before and at 1 month and 3 months after PDT. Retinal sensitivities within the retinal serous detachment before PDT, the PDT spot area, and the central area 2 degrees in diameter were evaluated.

Results: Fourteen of 16 eyes showed complete resolution of retinal detachment at 3 months after PDT. Mean retinal sensitivities within the retinal serous detachment before and at 1 month and 3 months after PDT were 8.9 dB, 12.1 dB, and 14.7 dB, respectively. Mean retinal sensitivities within the PDT spot area were 11.0 dB, 14.2 dB, and 15.7 dB, respectively. Mean retinal sensitivities in the central area 2 degrees in diameter were 6.0 dB, 9.9 dB, and 12.5 dB, respectively. Mean retinal sensitivities at both 1 month and 3 months after PDT showed statistically significant improvements as compared with before PDT (both, P < 0.05).

Conclusion: Photodynamic therapy with half-dose verteporfin appears to be an effective and safe treatment for patients with chronic chorioretinopathy, improving retinal sensitivity for at least 3 months.

Photodynamic therapy with half-dose verteporfin for treating chronic serous chorioretinopathy was evaluated. In 14 of 16 eyes, serous retinal detachment was absorbed. Retinal sensitivity at 3 months after photodynamic therapy with half-dose verteporfin was preserved or improved in patients with chronic central serous chorioretinopathy.

From the Department of Ophthalmology, Nihon University School of Medicine, Tokyo, Japan.

The authors have no conflicts of interest to disclose.

Reprint requests: Kyoko Fujita, MD, Department of Ophthalmology, Surugadai Hospital of Nihon University, 1-8-13 Surugadai, Kanda, Chiyoda-ku, Tokyo 101-8309, Japan; e-mail: kfujita@med.nihon-u.ac.jp

© The Ophthalmic Communications Society, Inc.